Keith Meister Sells 225,067 Shares of Illumina (NASDAQ:ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 225,067 shares of Illumina stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $145.55, for a total value of $32,758,501.85. Following the sale, the director directly owned 3,604,441 shares of the company’s stock, valued at $524,626,387.55. This trade represents a 5.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Illumina Stock Performance

Shares of Illumina stock traded down $1.76 on Thursday, hitting $143.24. The stock had a trading volume of 2,006,814 shares, compared to its average volume of 1,636,244. Illumina, Inc. has a 52-week low of $78.55 and a 52-week high of $155.53. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The stock has a market cap of $21.67 billion, a price-to-earnings ratio of 26.04, a P/E/G ratio of 2.40 and a beta of 1.42. The company’s 50 day moving average price is $128.31 and its 200 day moving average price is $129.43.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.05 by $0.10. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm’s revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, research analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current year.

Analysts Set New Price Targets

ILMN has been the topic of several research reports. Robert W. Baird set a $137.00 price objective on Illumina in a research report on Friday, February 6th. Barclays raised their target price on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. Weiss Ratings downgraded Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Wall Street Zen downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price for the company in a research note on Thursday. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Illumina has an average rating of “Hold” and a consensus price target of $137.75.

Institutional Investors Weigh In On Illumina

Hedge funds have recently made changes to their positions in the business. GC Wealth Management RIA LLC raised its holdings in Illumina by 1.1% during the first quarter. GC Wealth Management RIA LLC now owns 26,493 shares of the life sciences company’s stock worth $3,266,000 after purchasing an additional 296 shares in the last quarter. Gibbs Wealth Management raised its holdings in Illumina by 146.1% during the first quarter. Gibbs Wealth Management now owns 3,780 shares of the life sciences company’s stock worth $466,000 after purchasing an additional 2,244 shares in the last quarter. Sei Investments Co. raised its holdings in Illumina by 58.0% during the first quarter. Sei Investments Co. now owns 144,223 shares of the life sciences company’s stock worth $17,778,000 after purchasing an additional 52,914 shares in the last quarter. Lido Advisors LLC raised its holdings in Illumina by 19.3% during the first quarter. Lido Advisors LLC now owns 4,165 shares of the life sciences company’s stock worth $513,000 after purchasing an additional 675 shares in the last quarter. Finally, Cetera Investment Advisers increased its holdings in shares of Illumina by 6.7% in the first quarter. Cetera Investment Advisers now owns 28,547 shares of the life sciences company’s stock valued at $3,519,000 after buying an additional 1,791 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.